in addition, the license option agreement induces
a) an option to negotiate a licence for manufacturing CYP-001 product and
b) certain rights to Cynata's proprietary Cymerus technology for the prevention and treatment of other diseases.
Exercise of the rights to the additional components attracts further fees.This is what we want and the delay in time would be to negotiate this part of the deal, get a value on 001 then slap a big asking price for the other tech.
Going forward..., page-1124
-
- There are more pages in this discussion • 75 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.5¢ |
Change
-0.015(6.52%) |
Mkt cap ! $34.32M | |||
| Open | High | Low | Value | Volume |
| 22.5¢ | 22.5¢ | 21.5¢ | $15.12K | 67.95K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20000 | 22.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 22.5¢ | 100000 | 1 |
View Market Depth
| Last trade - 13.49pm 03/12/2024 (20 minute delay) ? |
| CYP (ASX) Chart |
